bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule
Inhibitors of Nsp14/nsp10 Exoribonuclease
Berta Canal1,6, Allison W. McClure1,6, Joseph F. Curran2,6, Mary Wu4, Rachel Ulferts3, Florian
Weissmann1, Jingkun Zeng1, Agustina P. Bertolin1, Jennifer C. Milligan1, Souradeep Basu2,
Lucy S. Drury1, Tom Deegan5, Ryo Fujisawa5, Emma L. Roberts2, Clovis Basier2, Karim
Labib5, Rupert Beale3, Michael Howell4 and John F.X Diffley1,*

1

Chromosome Replication Laboratory, the Francis Crick Institute, 1 Midland Road, London,

NW1 1AT
2

Cell Cycle Laboratory, the Francis Crick Institute, 1 Midland Road, London, NW1 1AT

3

Cell Biology of Infection Laboratory, the Francis Crick Institute, 1 Midland Road, London,

NW1 1AT
4

High Throughput Screening, the Francis Crick Institute, 1 Midland Road, London, NW1

1AT
5

The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences,

University of Dundee, Dundee DD1 5EH, UK
6

These authors contributed equally to this work

* Corresponding Author
john.diffley@crick.ac.uk
Tel: +44 (0) 203 796 1833

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Summary
SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world
causing a deadly pandemic with tremendous social and economic costs. Healthcare
systems worldwide are under great pressure, and there is urgent need for effective antiviral
treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an
inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic
activities of the non-structural proteins (nsp), which makes them interesting targets for the
development of new antiviral treatments. With the aim to identify novel SARS-CoV-2
antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor
(nsp10) and developed biochemical assays compatible with high-throughput approaches to
screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial
compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14
exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in
a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for
further coronavirus research as well as potentially contributing to new therapeutic
opportunities for COVID-19.

Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the human
coronavirus disease 19 (COVID-19) [1, 2]. The large number of infections and the severe
and long-term consequences of COVID-19 have greatly burdened healthcare systems
worldwide [3-6]. Lockdowns and ‚Äústay-at-home‚Äù orders have been the only effective strategy
to cut infections around the world, but they come with major societal and economic costs.
Long term solutions to the health and economic crises will rely on our ability to properly
monitor the evolution of the pandemic, on the effectiveness of novel vaccines, and on the
development of new antiviral treatments to prevent the loss of further lives until we are able
to control infections globally [7, 8].
Coronaviruses represent a threat to human health: in addition to SARS-CoV-2, two other
coronaviruses, SARS-CoV-1 and MERS-CoV, have been responsible for severe human
diseases this century [9]. Despite this, there is a lack of antiviral treatments for diseases
caused by coronaviruses [10, 11]. Currently, the only antiviral agent approved by regulatory
agencies for treatment of COVID-19 is remdesivir, a delayed chain-terminator nucleotide
analogue that impairs SARS-CoV-2 viral replication [12]. However, the WHO-funded
Solidarity trial failed to identify increased survival or reduced hospitalisation time in patients
treated with remdesivir, casting doubt on its effectiveness in treating COVID-19 [13-16].
SARS-CoV-2 is a betacoronavirus of the order Nidovirales with a positive-sense RNA strand

2

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

genome of approximately 30 Kb that encodes multiple open reading frames (ORF) [17, 18].
However, ORF1a and ORF1b represent two-thirds of the genome alone, and encode the 16
non-structural proteins of the virus (nsp1 - nsp16) [17]. The nsps include the 9 known viral
enzymatic activities, which are highly conserved among coronaviruses and of special
interest for the development of novel antiviral treatments, because of their important roles in
viral replication and lifecycle [19].
Among them, nsp14 protein is a bifunctional enzyme with an N-terminal 3‚Äô to 5‚Äô
exoribonuclease (ExoN) domain and a C-terminal S-adenosylmethionine (SAM)-dependent
N7-methyltransferase (MTase) domain [20-22]. The ExoN domain belongs to the DEDD
superfamily, which contains RNA and DNA exonucleases from all kingdoms of life, including
the proofreading domains of some E. coli DNA polymerases [23-25]. While the MTase
activity of nsp14 does not require a cofactor, the exonuclease activity of nsp14 is stimulated
by the cofactor nsp10 [23, 26].
It has been suggested that the exonuclease activity of nsp14 may act as a proofreader to
reduce the mutation rate of the virus [27-33]. Considering that most RNA viruses possess
small genomes and have high mutation rates, proofreading activity could be important to
maintain the integrity of the unusually large RNA genomes of coronaviruses including SARSCoV-2. Consistent with the hypothesis that nsp14 plays a role in proofreading during
replication, it associates with the viral RNA-dependent RNA polymerase (RdRp) complex
formed by nsp12 and its cofactors nsp7 and nsp8 [34, 35]. Also, mutation of the ExoN
domain of nsp14 in SARS-CoV-1 viruses resulted in viable viral progenies with high mutation
rates [28, 33]. However, similar ExoN mutations led to inviable virus progenies in MERSCoV and SARS-CoV-2, suggesting that the exonuclease activity of nsp14 could have other
essential roles in viral replication in these viruses [36]. Furthermore, coronavirus nsp14
exonuclease activity has been proposed to reduce the host innate antiviral immune
response by cleaving viral-associated double-stranded RNAs [37, 38] as well as to regulate
viral genome recombination [39]. Thus, the exonuclease activity of nsp14 might be required
for different aspects of viral genome replication and integrity and in other aspects of virus
proliferation, making it an attractive target for the development of new antiviral treatments of
COVID-19. Repurposing of previously characterised compounds for the treatment of novel
diseases is a fast and efficient approach [40, 41]. Here, we have purified the SARS-CoV-2
nsp14/nsp10 exonuclease and screened a custom collection of previously characterised
compounds with the aim to identify novel COVID-19 antivirals.

3

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Results
Purified SARS-CoV-2 nsp14/10 functions as an exoribonuclease in vitro
To obtain sufficient quantities of active SARS-CoV-2 nsp14 exonuclease and nsp10 cofactor
proteins for high-throughput screening, we tested a variety of protein tagging and expression
strategies (Supplementary Table S1 and S2). All protein purifications involved an initial step
based on an affinity tag followed by at least one other purification step (Supplementary
Table S3). We first expressed and purified nsp14 and nsp10 individually from Escherichia
coli (E. coli or ec) and baculovirus infected Sf9 insect cells (sf) (Figure 1A).
We tested nsp14 exoribonuclease activity using a double-strand RNA (dsRNA) substrate
with 7-nucleotide overhangs on both the 5‚Äô and 3‚Äô ends, with one strand 5‚Äô labelled with Cy5
(Cy5-dsRNA substrate) (Figure 1B). Reaction products were analysed on denaturing TBEurea polyacrylamide gels, where generation of faster migrating products indicates enzymatic
cleavage of the Cy5-dsRNA substrate. We did not observe cleavage of the Cy5-substrate in
the presence of individual nsp14(ec) and 3xFlag-6His-nsp14(sf) proteins alone (Figure 1C).
As shown previously [26], addition of increasing amounts of the cofactor nsp10 (nsp10-6His3xFlag(sf)) promoted the nuclease activity of nsp14 and, to a lesser extent, of 3xFlag-6Hisnsp14 (Figure 1D). In contrast to other reports [26], N-terminal tagged nsp10(ec) was unable
to stimulate nsp14 activity at similar concentrations (Figure 1D).
We also purified co-expressed nsp14/10 complexes (Figure 1E). When the nsp14 subunit
harboured the affinity tag for purification, the nsp10 subunit was less abundant and,
reciprocally, when the nsp10 subunit harboured the affinity tag for purification, the nsp14
subunit was less abundant, suggesting that the complex formed by nsp14 and nsp10 is not
stable stoichiometrically. Nevertheless, both nsp14/10 complexes co-expressed in E.coli or
insect cells showed nuclease activity comparable to the single nsp14 + nsp10-6His-3xFlag
proteins (Figure 1F and 1G).
Quantitative fluorescence assay for nsp14/10 exoribonuclease activity
To study nsp14/10 exonuclease activity and perform a high-throughput screen, we
developed a fluorescence-based assay using the intercalating Quant-itTM RiboGreen RNA
reagent (Figure 2A). We tested dilutions of RiboGreen against the Cy5-dsRNA substrate,
and found a wide linear range of fluorescence using a 1/400 dilution of RiboGreen (Figure
2B and Supplementary Figure S1). RiboGreen fluorescence decayed after prolonged
incubation in our reaction buffers (Figure 2C), so all subsequent experiments were analysed
immediately after RiboGreen addition. To evaluate nsp14/10 exonuclease activity with the
RiboGreen assay, we took the samples shown in Figure 1F and incubated them with

4

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

RiboGreen. As predicted, RiboGreen fluorescence decreased with increasing amounts of
nsp14/10 consistent with exoribonuclease activity (Figure 2D).
nsp10-14 fusion functions as an efficient exoribonuclease
The untagged subunit in the nsp14/10 complex preparations tended to be substoichiometric
(Figure 1E), and relatively high amounts of nsp10 were required to stimulate nsp14 (Figure
1D), suggesting that the nsp14/10 complex might not be stable. We therefore wondered if
direct fusion of nsp10 to nsp14 would generate a more active enzyme. A similar strategy
was successful with the SARS-CoV-1 proteins nsp12/7/8, which purify as a more active
polymerase complex when nsp7 and nsp8 are fused together with a short linker [34]. To test
this, we expressed nsp14-linker-nsp10 (nsp14-10) and nsp10-linker-nsp14 (nsp10-14) fusion
proteins in E. coli (Figure 3A and 3B). The nsp10-14 fusion cleaved the Cy5-dsRNA
substrate in both the gel and RiboGreen assays (Figure 3C). Titration of nsp10-14 fusion
protein showed high exonuclease activity with as little as 1-3 nM of protein compared to
about 200 nM needed for the nsp14/10 co-expressed complex (Figure 3D). The nsp14-10
fusion protein also showed high exonuclease activity (Figure 3D). To avoid any interference
between Cy5 and RiboGreen, we then titrated the nsp10-14 fusion in the presence of an
unlabelled version of the Cy5-dsRNA substrate (Figure 2A and Supplementary Table S4),
which resulted in exonuclease activity (Figure 3E) comparable to that observed with the Cy5
substrate (Figure 3D). Nsp14 is also an N7-guanine cap methyltransferase and the nsp1014 fusion retains this methyltransferase activity (Supplementary Figure S2).
Screens for SARS-CoV-2 nsp14/10 inhibitors
The quantitative nature of the RiboGreen assay enabled us to determine the MichaelisMenten constant (KM) of the nsp10-14 fusion protein for the unlabelled dsRNA substrate to
be 66 nM (Supplementary Figure S3A and S3B). We then carried out a high-throughput
screen to identify nsp14/10 exonuclease inhibitors from a custom library of over 5000
commercial compounds. The screen had a robust signal to noise ratio between positive and
negative controls, and a mean Z‚Äô factor of 0.72, and we detected many compounds
apparently able to reduce nsp14/10 exonuclease activity at both concentrations screened
(Supplementary Figure S3C). In the RiboGreen assay, fluorescence is highest at time zero
of the exonuclease reaction, and cleavage of the substrate leads to reduced fluorescence
signals (Figure 2D or 3D as examples). Thus, inhibition of exonuclease activity is expected
to decrease the cleavage-dependent reduction in RiboGreen fluorescence. Based on this, to
identify putative inhibitors of nsp14/10 exonuclease, we selected compounds that led to
higher final fluorescence signals than control reactions. However, when we were validating
these compounds, we found that many were auto-fluorescent in the wavelength range of

5

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

RiboGreen fluorescence (Supplementary Figure S3D). Because of this, we could not
feasibly distinguish true hit compounds from auto-fluorescent false hits using this approach.
We decided to perform a second fluorescence-based high-throughput screen against the
same library but using a different assay which utilises a different wavelength. For the new
assay, we used an RNA duplex substrate with a 20-nucleotide 5‚Äô dU overhang, conjugated
to a Cy3-quencher pair (Figure 4A and Supplementary Table S4). Using this substrate,
nucleolytic cleavage by nsp10-14 fusion protein released the Cy3 fluorophore strand from
the quencher strand and produced fluorescent signal (Figure 4A and 4B). When a DNA
version of this substrate was used, only background levels of fluorescence were detected
(Figure 4B). This indicated that, as expected, nsp10-14 is unable to cleave DNA substrates
and that the fluorescence in reactions with the Cy3-dsRNA substrate is not due to unspecific
factors such as temperature-dependent unwinding. When using this substrate, we were able
to obtain kinetic data of the enzyme compared to the end-point information obtained when
using our previous RiboGreen approach. We, thus, monitored fluorescence over time and
titrated the substrate, which gave an estimated KM of 40 nM (Figure 4C and 4D). The
estimated KM was similar to our previous estimation using the RiboGreen assay (66 nM)
(Supplementary Figure S3A and S3B), and therefore we decided to perform this second
screen using 50 nM of substrate, as we did in the first screen. At 50 nM of substrate, we
assessed nuclease activity over a range of enzyme concentrations and chose to do the
reactions in the screen for 10 minutes with 0.5 nM of nsp10-14 fusion protein (Figure 4E).
As performed in the first screen, the drug library was screened at 1.25 ¬µM and 3.75 ¬µM.
First, nsp10-14 was incubated with the compounds for 10 min prior to the addition of the
substrate, then fluorescent measurements were taken every minute for 10 min. The activity
of nsp10-14 was defined as the slope of the reaction over the linear range. Again, the screen
had a robust signal to noise ratio between positive and negative controls and a mean Z‚Äô
factor of 0.86. The activity of nsp10-14 was normalised to the control wells without
compounds (see Experimental Procedures). Both compound concentrations produced hits
with residual activities less than 1 (Figure 4F). We considered compounds that reduced
nsp10-14 activity below 80% in both concentrations, showed a Z score less than -5 (Figure
4G), and also showed some reduction in the first screen with RiboGreen detection. We also
considered compounds that showed stronger inhibition in the higher dose in both screens,
even if the absolute inhibition was not as strong as our initial cut-offs. We discounted some
compounds for having a high aggregation index (>3 or known aggregators) [42] and for
appearing in multiple screens (see accompanying manuscripts).

6

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Validation of hits
Taking the results from both screens into consideration, we tested 12 compounds in
validation experiments (Supplementary Table S5). We returned to the gel-based assay with
the Cy5-dsRNA substrate for validation. The nsp10-14 fusion protein was incubated with the
hit compounds for 10 minutes prior to substrate addition as in the screens, and the reactions
were stopped at 5 min instead of the usual 30 min reactions, to allow for the visualization of
both the full-length RNA strand and the cleaved products. Two compounds inhibited nsp1014 exonuclease activity in a concentration-dependent manner at both 5 ¬µM and 25 ¬µM:
patulin and aurintricarboxylic acid (ATA) (Figure 5A). We also tested whether patulin
inhibited the co-purified complex nsp14/10 in addition to nsp10-14 fusion protein. Indeed,
patulin inhibited both fusion and complex when in ~ 5000 fold excess of enzyme (Figure 5B,
5C lanes 2 - 5, and Supplementary Figure S4A).
To determine how specific patulin and ATA are to nsp10-14, we tested whether they
inhibited other nucleases such as RNase A and benzonase. We titrated RNase A and
benzonase to select enzyme concentrations that allowed us to visualise both full-length RNA
and cleaved products in gel-based assays after 5 min (Supplementary Figure S4B). Patulin
did not inhibit RNase A or benzonase up to 50 ¬µM, suggesting that it is not a general
nuclease inhibitor (Figure 5C). Despite the fact that ATA has been described as a general
inhibitor of nucleases and other DNA binding enzymes [43], we observed only minor
inhibition of RNase A and benzonase at 50 ¬µM ATA (Figure 5D). In contrast, we observed
inhibition of nsp10-14 from 5 ¬µM ATA, indicating that it inhibits nsp10-14 at lower
concentrations than it inhibits RNase A and benzonase (Figure 5D).
To characterise the inhibition kinetics of patulin and ATA (chemical structures in
Supplementary Figure S4C and S4D) on nsp14/10 exonuclease, we determined the half
maximal inhibitory concentration (IC50) of these compounds. To calculate the IC50s, we
incubated increasing concentrations of patulin or ATA with nsp10-14 protein following the
scheme of the screen and calculated the exonuclease activity of nsp10-14 at each drug
concentration in the presence of the Cy3-dsRNA substrate (see Experimental Procedures).
Patulin showed an IC50 of 1.8 ¬µM (95% CI 1.6 - 2.1 ¬µM) and ATA showed an IC50 of 10.3 ¬µM
(95% CI 8.6 - 12.1 ¬µM) (Figure 5E and 5F and Supplementary Figures S4E and S4F).
Importantly, in all the concentrations assayed, patulin and ATA do not quench Cy3
fluorescence (Supplementary Figure S4G and S4H).
Effects of patulin and aurintricarboxylic acid on viral growth
To explore if patulin and ATA could serve as antiviral drugs against SARS-CoV-2, we
performed infectivity assays using VERO E6 cells in the presence of increasing
concentrations of patulin and ATA. SARS-CoV-2 nsp14 exonuclease activity has been
7

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

recently proposed to be essential for viral proliferation, and thus we expected that if patulin
and ATA were able to inhibit nsp14 exonuclease also in cells, we would observe reduced
viral infectivity [36]. Virus in VERO E6 cells 22 hours post-infection (MOI 0.5 PFU/cell) was
detected by immunofluorescence with an antibody raised against the SARS-CoV-2
nucleocapsid (N) protein (see Experimental Procedures). Viral proliferation was reduced in
the presence of patulin at ~ 5-10 ¬µM (Figure 6A and 6B). Above 10 ¬µM, patulin decreased
cell viability of cultured VERO E6 (Figure 6A and 6B). Similarly, we observed reduced viral
proliferation in the presence of ATA in a dose-dependent manner from ~ 3-100 ¬µM (Figure
6C). At the concentrations tested, ATA did not affect cell viability (Figure 6C).
Combining different antivirals is effective in treating viral infections and reducing treatment
resistance [44]. To this end, we performed the SARS-CoV-2 infectivity assays in the
presence of patulin or ATA in combination with the SARS-CoV-2 antiviral remdesivir. When
combined, the dose-response curves of patulin and ATA were not shifted in response to a
low dose (0.5 ¬µM) of remdesivir, indicating that, under the conditions tested, these drugs do
not synergise (Figure 6D and 6E). We also performed the reciprocal experiment testing
whether patulin would alter the remdesivir dose-response curve, but we did not observe any
shift in the remdesivir curve in the presence of 3 ¬µM or 5 ¬µM patulin (Supplementary Figure
S5).

Discussion
Previously, nsp14/nsp10 exonuclease activity had only been studied by monitoring cleavage
of RNA substrates in gel-based assays using an excess of enzyme over substrate
concentration [26, 36, 45, 46]. In this study, we have purified a fusion protein of nsp14 and
nsp10 that shows ~ 100 fold higher exoribonuclease activity than the co-expressed or single
nsp14 and nsp10 proteins. Further, we developed fluorescence-based assays for nsp14/10
exoribonuclease activity in solution, which are also scalable for high-throughput screens. We
used these assays to screen for nsp14/10 exoribonuclease inhibitors among a custom
chemical library of over 5000 commercial compounds and identified patulin and
aurintricarboxylic acid (ATA) as inhibitors of SARS-CoV-2 nsp14/10 exonuclease.
The exoribonuclease (ExoN) domain of nsp14 is highly conserved among the nidoviruses
that possess large genomes (>20 Kb), however, the function of ExoN for viral proliferation is
still unclear. In addition to its proposed role as proofreader, nsp14/10 is thought to promote
host innate immune evasion by cleaving dsRNA molecules and participate in viral genome
recombination [37, 39, 47, 48]. ExoN is essential in SARS-CoV-2 [36], so patulin and
aurintricarboxylic acid (ATA), the new inhibitors of nsp14/10 exonuclease activity identified
here, represent new tools to acutely inhibit ExoN activity during viral growth, which should be

8

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

valuable for understanding the role of nsp14/10 ExoN during the viral life cycle. Also,
considering the role of nsp14/10 in immune suppression, we speculate that even mild
inhibition of nsp14/10 ExoN by patulin and ATA could lead to accumulation of highly
immunogenic dsRNA molecules and promote strong immune antiviral responses.
A proofreader activity of nsp14 could reduce the effectiveness of nucleotide analogue chain
terminators such as remdesivir by preventing their incorporation or removing them [49].
Supporting this, ExoN mutants of murine hepatitis virus (MHV), a type of coronavirus, were
shown to have 4.5-fold higher sensitivity to remdesivir treatment [12]. However, our results in
VERO E6 cells did not show any synergy of patulin or ATA with remdesivir (Figure 6C and
6D). Remdesivir acts as a delayed chain terminator where RNA synthesis stops about 3
nucleotides after its incorporation and perhaps nsp14/10 does not have access to remove it.
It would be interesting for future studies to examine whether patulin and ATA synergise with
immediate chain terminators and to further explore how nsp14/10 might act as a
proofreader.
ATA has been used as a positive control drug for nuclease inhibition due to its known roles
as a general nuclease and DNA binding inhibitor [43, 50]. Indeed, ATA has recently been
used as a control to inhibit nsp14/nsp10 exoribonuclease using a biochemical gel-based
assay [51]. However, our results show that ATA inhibits nsp14/nsp10 exoribonuclease
activity at much lower concentrations than the concentration needed to inhibit other
nucleases such as RNase A and benzonase (Figure 5D), suggesting that ATA has specific
activity towards SARS-CoV-2 nsp14/nsp10 compared to other nucleases. We cannot rule
out the possibility that some of the antiviral activity of ATA is due to inhibition of other
nucleases besides nsp14/10. ATA has been shown to inhibit replication of several other
viruses including SARS-CoV-1 and Zika [52, 53], and studies using cell culture and animal
models have shown limited toxicity of ATA [53-55]. Further studies will be needed to
understand the putative use of ATA for the inhibition of SARS-CoV-2 and treatment of
COVID-19.
Patulin is a lactone mycotoxin produced by several species of Penicillium and Aspergillus,
commonly found in foodstuffs such as rotting apples [56]. Patulin has antimicrobial effects
and it has been shown to have cytotoxic, apoptotic and genotoxic effects in mammalian
cells, including cancer cells [56-59]. While patulin does show some cellular toxicity in our
assays, structural analogues of patulin were shown to have reduced toxicity compared to
patulin in cell culture models [60], providing an opportunity to study alternative patulin-like
molecules for the development of novel antiviral agents against coronaviruses. Also,
considering that even mild inhibition of nsp14/10 exonuclease could have an effect on host
immune responses, low and transient doses of patulin could also be considered. After some
9

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

initially promising results in the early 20th century, patulin was tested in a clinical trial for its
ability to treat the common cold but found to be ineffective [61]. Since the time of this MRC
trial, it has been shown that many viruses in addition to coronaviruses can cause the
common cold, so it is likely that if patulin was effective only in treating coronavirus-based
colds, the trial would not have uncovered it. It will be interesting for future studies to test
patulin in the treatment of both COVID-19 and other coronavirus diseases.

Materials and Methods
Expression constructs and protein expression in E.coli
The sequences of SARS-CoV-2 nsp14 and nsp10 (NCBI reference sequence NC_045512.2)
were codon optimised for expression in E. coli using the GeneArt Gene Synthesis software
(ThermoFisher scientific) and genes were ordered from GeneWiz (codon optimised DNA
sequences in supplementary information). The HiFi DNA Assembly system (NEB) was used
to build the plasmids to express individual, complex and fusion proteins (Supplementary
Table S1 and S3). Individual nsp10 was expressed from plasmid SARS-CoV-2 3xFlagnsp5CS-nsp10 (Addgene ID 169157) containing the N-terminal 3xFlag tag
(MDYKDHDGDYKDHDIDYKDDDDK). Untagged individual nsp14 (nsp14) was expressed
from plasmid DU70487 that contains non-codon optimised nsp14 gene cloned into plasmid
pK27SUMO (gene synthesis at MRC PPU available from https://mrcppu-covid.bio). To coexpress nsp14/10 complex, we co-transformed plasmids SARS-CoV-2 nsp10 (Addgene ID
169158) and SARS-CoV-2 3xFlag-nsp5CS-nsp14 (Addgene ID 169159). To express nsp1014 and nsp14-10 fusion proteins, nsp10 and nsp14 genes from plasmids 169157 and
169159 were cloned in frame with the N-terminal 14His-K27SUMO tag of plasmid
pK27Sumo [62], including a GGSGGS linker between both nsp proteins (Figure 3A).
For expression of the nsp10-14 fusion protein, T7 Express LysY competent cells from NEB
(C3010I) were transformed with plasmid pEcoli-Cov_42 (Supplementary Table S2) and
grown overnight (ON) at 37¬∫C in LB media supplemented with 50 ¬µg/ml kanamycin.
Saturated cultures were diluted in 10 L to an OD595 of 0.1 and grown at 37¬∫C until OD595 of
0.4. Cultures were then cooled down to 16¬∫C on ice, after which protein expression was
induced ON at 16¬∫C by adding 0.4 mM IPTG. Cells were harvested by centrifugation,
washed once in 1x TBS, and the pellet was frozen in liquid nitrogen. All steps after this point
were carried out at 4¬∫C. Pellets were resuspended to 30 mL with lysis buffer (50 mM TrisHCl pH 7.5, 0.05 % NP-40, 10 % glycerol, 500 mM NaCl, 1 mM DTT and 30 mM imidazole)
+ cOmplete‚Ñ¢ EDTA-free Protease Inhibitor Cocktail (Sigma). Cells were lysed for 30 min on
ice by addition of 0.33 mg/ml lysozyme followed by sonication (5 sec on/5 sec off at 35% for
3 min), and cell debris was cleared by centrifugation at 20,000 rpm for 30 min.

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Expression constructs and protein expression in baculovirus-infected insect cells
Plasmids SARS-CoV-2 nsp10-His-3xFlag (Addgene ID 169162), SARS-CoV-2 3xFlag-His-nsp5CSnsp14 (Addgene ID 169163) and SARS-CoV-2 nsp14/nsp10-His-3xFlag (Addgene ID 169164)

were expressed in baculovirus-infected Sf9 insect cells. The coding sequences of SARSCoV-2 nsp10 and nsp14 (NCBI reference sequence NC_045512.2) were codon-optimised
for S. frugiperda ordered from GeneArt (Thermo Fisher Scientific) (codon optimised DNA
sequences can be found in supplementary information). Baculoviral expression vectors were
generated using the biGBac vector system [63]. Nsp10 was subcloned into a modified
pBIG1b vector containing a pLIB-derived polyhedrin expression cassette to contain a Cterminal 6His-3xFlag tag (sequence: nsp10GGSHHHHHHGSDYKDHDGDYKDHDIDYKDDDDK). Nsp14 was subcloned into a modified
pBIG1a vector containing a pLIB-derived polyhedrin expression cassette to either contain an
N-terminal 3xFlag-6His tag (sequence:
MDYKDHDGDYKDHDIDYKDDDDKGSHHHHHHSAVLQ-nsp14) or no tag to generate
SARS-CoV-2 nsp14/nsp10-His-3xFlag (Addgene ID 169164). Baculoviruses were generated

and amplified in Sf9 insect cells (Thermo Fisher Scientific) using the EMBacY baculoviral
genome [64]. For protein expression, Sf9 insect cells were infected with baculovirus and
collected 48 h after infection, flash-frozen and stored at -70 ¬∞C. Pellets were lysed with a
Dounce homogeniser, 3 x 10 strokes on ice and cell debris cleared by centrifugation at
20,000 rpm for 30 min.
Protein purification
For the purification of the nsp10-14 fusion protein, 1 ml slurry of HisPurTM Ni-NTA resin
equilibrated in lysis buffer was added to the cleared lysate and rotated for 2 h. Resin was
collected by centrifugation at 1000 x g for 2 min, washed with 100 ml lysis buffer and
incubated for 20 min in 10 ml elution buffer (lysis buffer with 400 mM imidazole). Eluate was
dialysed ON against 1.5 L of dialysis buffer (25 mM Tris-HCl pH 7.5, 0.02 % NP-40, 10 %
glycerol, 100 mM NaCl, 1 mM DTT and 30 mM imidazole) + 20 ¬µg/ml Ulp1-cat-6His, and
passed over 0.5 ml HisPurTM Ni-NTA resin pre-equilibrated in dialysis buffer to remove Ulp1.
The flowthrough was applied to a MonoQ (5/50 GL, GE healthcare) equilibrated in Buffer
100 (25 mM Tris-HCl pH 7.5, 0.02 % NP-40, 10 % glycerol, 1 mM DTT and 100 mM NaCl),
washed with 10 CV Buffer 100 and eluted over a 20 CV linear gradient to Buffer 1000 (25
mM Tris-HCl pH 7.5, 0.02 % NP-40, 10 % glycerol, 1 mM DTT and 1000 mM NaCl). The
nsp14-10 and nsp10-14 fusion proteins eluted at ~ 400 mM NaCl. Peak fractions were
pooled, concentrated to ~ 0.4 ml with a 30KDa Amicon Ultra Centrifugal filter and separated
on a Superdex 200 Increase 10/300 GL column equilibrated in Buffer 150 (25 mM Tris-HCl
pH 7.5, 0.02 % NP-40, 10 % glycerol, 1 mM DTT, 4 mM MgCl2 and 150 mM NaCl). Peak

11

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

fractions were pooled, aliquoted and frozen in liquid nitrogen to be stored at -80¬∫C. Protein
concentration was determined by Bradford and by comparing to a BSA standard curve on a
Coomassie stained SDS-PAGE gel. The nsp10-14 fusion protein concentration was at 1.1
mg/ml (yield ~ 0.4 mg protein / L cell culture).
Modifications of this protocol were used to purify the other recombinant proteins
(Supplementary Table S3). Purifications using 3xFlag tag were performed similarly with the
following modifications: 1 ml slurry of ANTI-FLAG M2 Affinity gel (Sigma) equilibrated in flag
lysis buffer (50 mM Tris-HCl pH 7.5, 0.05 % NP-40, 10 % glycerol, 500 mM NaCl, 1 mM
DTT) was added to the cleared lysate and rotated for 2 h. Resin was collected by
centrifugation at 1000 x g for 2 min, washed with 100 ml flag lysis buffer and incubated for
30 min in 10 ml flag elution buffer (50 mM Tris-HCl pH 7.5, 0.05 % NP-40, 10 % glycerol,
300 mM NaCl, 1 mM DTT) + 0.5 mg/ml 3xFLAG peptide. Eluate was diluted 3-fold with No
salt buffer (50 mM Tris-HCl pH 7.5, 0.05 % NP-40, 10 % glycerol, 1 mM DTT) to be applied
to a MonoQ or concentrated to ~ 0.4 ml with a 30KDa Amicon filter for gel filtration.
Expression and purification of Ulp1-cat-6His protease
T7 Express LysY competent cells transformed with plasmid pFGET19-Ulp1 (Addgene
64697) were grown to OD595 of 0.8 at 37¬∫C in 2 L LB media supplemented with 50 ¬µg/ml
kanamycin (ON culture at 37¬∫C without shaking). Expression was induced for 4 h at 37¬∫C
with shaking by the addition of 1 mM IPTG. Pellet was resuspended in lysis buffer (50 mM
Tris-HCl pH 8, 0.02% NP40, 10% Glycerol, 500 mM NaCl, 5 mM MgOAc, 1 mM DTT) + 20
mM imidazole + protease inhibitors (10 ¬µg/ml Pepstatin -P4265 Sigma-, 10 ¬µg/ml Leupeptin
-108975 Merck-, 1 mM AEBSF -A8456 Sigma-) and cells were lysed by lysozyme and
sonication. 0.5 ml slurry of HisPurTM Ni-NTA resin equilibrated in lysis buffer was added to
the cleared lysate and rotated for 1 h at 4¬∫C before washing with 50 ml lysis buffer and
eluted in lysis buffer + 250 mM imidazole. Eluate was concentrated to ~ 0.4 ml with a 10KDa
Amicon Ultra Centrifugal filter and separated in a Superdex200 Increase 10/300 GL column
equilibrated in storage buffer (50 mM Tris-HCl pH 8, 0.01% NP40, 10% Glycerol, 500 mM
NaCl, 5 mM MgOAc, 0.5 mM TCEP). Peak fractions were pooled, and aliquots were frozen
in liquid nitrogen and stored at -80C. Ulp1 eluted at ~ 13 ml, and protein concentration was
determined by Bradford at 2 mg/ml.
RiboGreen exonuclease assay
For substrate preparation, oligos i (unlabelled) and iii (unlabelled) (Supplementary Table S4)
were diluted to 100 ¬µM in RNase-free water, then mixed to a final concentration of 10 ¬µM
each in 20 mM Tris-HCl (pH 7.5) and 50 mM NaCl in 50 ¬µl. Mix was heated at 98¬∫C for 2 min
and then cooled to 4¬∫C in 700 cycles of 4 sec each (-0.1¬∫C/cycle).

12

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

End-point nuclease assays (20 ¬µl) were performed at room temperature (RT) in reaction
buffer 1 (25 mM Tris-HCl pH 7.5, 0.02 % Tween20, 10 % glycerol, 1.5 mM MgCl2, 20 mM
NaCl, 0.1 mg/ml BSA and 0.5 mM TCEP). Enzyme and substrate were diluted in reaction
buffer 1 at the concentration specified in each figure legend. Reactions were stopped by the
addition of 30 ¬µl Stop/RiboGreen mix (25 mM Tris-HCl pH 7.5, 0.1 mg/ml BSA, 20 mM EDTA
and a 1/250 dilution of Quant-iT‚Ñ¢ RiboGreen¬Æ RNA reagent, ThermoFisher Scientific) after
which fluorescence was read in black 384-well plates (GRE384fb 781076) using a Spark
Multimode microplate reader (Tecan) with the following settings: Excitation 485 nm /
Emission 530 nm (20/20 bandwith), Gain 94, 30 flashes, Z position of 18843.
Cy5 gel-based exonuclease assay
Substrate preparation was performed as for the RiboGreen assay, using oligos ii (Cy5) and
iii (unlabelled) (Supplementary Table S4). End-point nuclease assays were performed
essentially as the RiboGreen assays except that reactions were stopped (1:1) with 2X
sample buffer (98% Formamide, 10 mM EDTA). Samples were denatured at 95¬∫C for 2 min
and loaded on 7M-urea polyacrylamide-1X TBE denaturing gels and run in 1x TBE running
buffer at 180 V for 2 to 3 hours at RT before Cy5 fluorescence was visualised with an
Amersham Imager 600, GE lifesciences.
Cy3/quencher-based exonuclease assay (kinetic)
For Cy3- substrates preparation, RNA oligos iv (Cy3) and v (quencher) or DNA oligos vi and
vii were mixed at a 1:1.2 ratio with Cy3 oligo to 20 ¬µM and Iowa Black RQ quencher oligo to
24 ¬µM (Supplementary Table S4). For RNA substrate, samples were heated at 75¬∫C for 3
min and then cooled to 5¬∫C in 700 cycles of 4 seconds each (-0.1¬∫C/cycle) after which
substrate was aliquoted and stored at -20¬∫C. For DNA substrate, samples were heated at
95¬∫C for 5 min and then cooled down to 21¬∫C in 740 cycles of 1 second each (-0.1¬∫C/cycle),
aliquoted and stored at -20¬∫C.
Cy3/quencher-based kinetic nuclease assays (20 ¬µl) were performed at room temperature
(RT) in reaction buffer 2 (50 mM Tris-HCl pH 7.5, 0.01 % Tween20, 10 % glycerol, 1.5 mM
MgCl2, 20 mM NaCl, 0.1 mg/ml BSA and 0.5 mM TCEP). Enzyme and substrate were
diluted in reaction buffer 2 at the concentration specified in each figure legend. Progression
of the reactions was monitored every min by fluorescence in black 384-well plates
(GRE384fb 781076) using a Spark Multimode microplate reader (Tecan) with the following
settings: Excitation 545 nm / Emission 575 nm (10/10 bandwith), Gain 147, 10 flashes, Z
position of 17800.

13

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Methyltransferase assay
The methyltransferase activity of nsp10-14 was assayed by the detection of released SAH
from the methyltransferase reaction. Released SAH was detected through the use of the
commercially available EPIgeneous‚Ñ¢ methyltransferase kit (CisBio Bioassays). Individual
kit reagents were reconstituted according to the manufacturer‚Äôs instruction. The
methyltransferase reaction was conducted at room temperature in an 8 Œºl reaction volume
with 10 nM nsp10-14, 1 ŒºM Ultrapure SAM (CisBio), 0.14 mM GpppA RNA cap analogue
(New England Biolabs) in reaction buffer consisting of HEPES-KOH pH 7.6, 150 mM NaCl,
and 0.5 mM DTT. The reaction was started with the addition of nsp10-14 and was allowed to
proceed for 20 minutes before quenching by the addition of 2 Œºl 5M NaCl to a final
concentration of 1M.
Following quenching, 2 Œºl Detection Buffer 1 (CisBio) was immediately added to the reaction
mixture. After 10 minutes, 4 Œºl of 16X SAH-d2 conjugate solution (CisBio) was added. 16X
SAH-d2 was prepared by adding one part SAH-d2 to 15 parts Detection Buffer 2 (CisBio).
After 5 minutes, 4 Œºl of 1X Œ±-SAH Tb Cryptate antibody solution was added to the reaction
mixture. 1X Œ±-SAH Tb Cryptate antibody solution was prepared by adding one part Œ±-SAH
Tb Cryptate antibody (CisBio) to 49 parts Detection Buffer 2 (CisBio).
Homogenous Time Resolved Fluorescence (HTRF) measurements were taken after 1 hour
following Œ±-SAH Tb Cryptate antibody addition on a Tecan Infinite M1000 Pro plate reader.
Readings were taken with a lag time of 60 Œºs after excitation at Œª=337 nm. Readings were
taken at emission wavelengths of Œª=665nm and Œª=620nm. The experimental HTRF ratio
(HTRFexp) was then calculated as ratio of emission intensities: Œª=665/Œª=620. To reach the
normalised HTRF ratio, HTRF ratio measurements were also taken of wells without enzyme
(E0) and without SAH-d2 (d20), representing the maximum and minimum achievable HTRF
values, respectively. The normalised HTRF ratio was then calculated as a linear
transformation of the experimental HTRF ratio, the E0 ratio, and the d20 ratio:
ùëÅùëúùëüùëöùëéùëôùëñùë†ùëíùëë ùêªùëáùëÖùêπ =

ùêªùëáùëÖùêπ!"# ‚àí ùëë2$
ùê∏$ ‚àí ùëë2$

Screening library
High-throughput screening was performed using a custom compound collection assembled
from commercial sources (Sigma, Selleck, Enzo, Tocris, Calbiochem, and Symansis). 2.5 or
7.5 nl of a 10 mM stock of the compounds dissolved in DMSO were arrayed and dispensed
into square flat-bottom black 384-well plates containing 1 ¬µl DMSO/well using an Echo 550
(Labcyte), before being sealed and stored at -80¬∞C.

14

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

RiboGreen-based screen (first)
All steps and reagents were kept at room temperature (RT) during the day of the screen.
The morning of the screen all plates were moved from -80¬∫C to 4¬∫C. From there, plates were
moved to RT 30 min before centrifuging and de-sealing. The RiboGreen screen was
performed in three main steps which required the use of three independent XRD-384
Reagent Dispensers (FluidX Ltd.) each loaded with 16-channel tubing and set at high speed.
First, 10 ¬µl of 2X enzyme mix (10 nM nsp10-14 fusion protein in 1X reaction buffer 1) was
dispensed in columns 1 to 23 and incubated ‚ÄúEnzyme + drugs‚Äù for 10 min. After each
dispensing, plates were centrifuged for <1 min at 4000 rpm. Second, 10 ¬µl of 2X substrate
mix (100 nM unlabelled dsRNA substrate in 1x reaction buffer 1) was dispensed in columns
2 to 24, and 10 ¬µl reaction buffer 1 were pipetted by hand to control columns 1 and 24. After
5 min, 30 ¬µl of Stop/RiboGreen mix (final concentration in 50 ¬µl: 25 mM Tris-HCl pH 7.5, 0.1
mg/ml BSA, 20 mM EDTA and a 4000-fold dilution of Quant-iT‚Ñ¢ RiboGreen¬Æ RNA reagent)
was dispensed in columns 1 to 24. After 2 min, fluorescence in all wells was read using a
Spark Multimode microplate reader (Tecan) with the following settings: Excitation 485 nm /
Emission 530 nm (20/20 bandwith), Gain 94, 30 flashes, Z position of 18843. Plates were
processed one after the other, with ~ 7 min delay between them.
Cy3/quencher-based kinetic screen (second)
All steps and reagents were kept at RT during the days of the screen except the stock of
enzyme mix that was kept in ice. The morning of the screen, all plates were moved from 80¬∫C to 4¬∫C. From there, plates were moved to room temperature for 30 min before
centrifuging and de-sealing. This second screen was performed in two main steps which
required the use of two independent XRD-384 Reagent Dispensers (FluidX Ltd.) each
loaded with 16-channel tubing and set at high speed. First, 10 ¬µl of 2X enzyme mix (1 nM
nsp10-14 fusion enzyme in 1X reaction buffer 2) was dispensed in columns 1 to 23, and 10
¬µl reaction buffer 2 were pipetted by hand to control columns 1 and 24. After 10 min, 10 ¬µl of
2X substrate mix (100 nM Cy3/quencher RNA substrate in 1x reaction buffer 2) was
dispensed in columns 2 to 24 and, after 2 min, started reading fluorescence in all wells every
1 min for 10 min using a Spark Multimode microplate reader (Tecan) with the following
settings: Excitation 545 nm / Emission 575 nm (10/10 bandwith), Gain 147, 10 flashes, Z
position of 17800. Plates were processed one after the other, with ~ 20 min delay between
them.
Screen data analysis
Screen data were analysed with custom MATLAB and R scripts. For the RiboGreen screen,
normalised residual activity was calculated for each well, relative to the controls on that

15

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

plate. The median background fluorescence, calculated from 8 wells containing no
substrate, was subtracted from all wells, before normalisation using the formula:
1‚àí

ùëÄ%&" ‚àí ùë•
ùëÄ%&" ‚àí ùëÄ%'(

where ùëÄ!"# is the median of 8 wells without enzyme (maximum signal), ùëÄ!$% is the median
of 16 wells with no drug (minimum signal) and ùë• is the experimental value.
For the second Cy3/quencher-based screen, the slope of each reaction over the first 6 min
was calculated by linear regression and then was normalised by dividing by the average of
the control wells without drugs in each row of the plate.
In both screens, Z scores were then calculated for each experimental well.
ùëç=

ùë• ‚àí ùëÄ&))
ùúé&))

where ùë• is the normalised experimental value, and ùëÄ"&& and ùúé"&& are the median and
standard deviation of all 6106 normalised samples at that concentration respectively.

Z‚Äô factors were calculated for each plate to determine screen quality.
ùëç* = 1 ‚àí

3ùúé#+, + 3ùúé(!;ùúá#+, ‚àí ùúá(!- ;

where ùúá'() and ùúé'() are the mean and standard deviation of the positive controls (no drugs)
respectively, and ùúá%*+ and ùúé%*+ are the mean and standard deviation of the negative
controls (no enzyme) respectively.
KM and IC50 calculation
For the unlabelled dsRNA substrate, we calculated the initial velocity of the reactions
considering 0, 3 and 6 minutes in the presence of 5 nM of nsp10-14 fusion protein and 15.65
- 250 nM substrate by linear regression. Slopes were then used to calculate KM and VMAX by
non-linear fitting to the Michaelis-Menten equation using GraphPad Prism.
For the Cy3-dsRNA substrate, we determined the maximum velocity over the first 45
minutes of the reactions in the presence of 0.5 nM of nsp10-14 fusion protein and 15.65 500 nM substrate by calculating the maximum of the first derivative. Slopes were then used
to calculate KM and VMAX by non-linear fitting to the Michaelis-Menten equation using
GraphPad Prism.
Similarly, we determined maximum velocity of the reactions in the presence of 0.5 nM
nsp10-14, 50 nM Cy3/Q-substrate and a titration of patulin or ATA (0 - 160 ¬µM) over 15 min

16

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

by calculating the maximum of the first derivative. Slopes were then used to calculate the
percentage of activity relative to the slope without inhibitor. Percent activity for each log10 of
the concentration of patulin or ATA were then used to estimate the IC50 and Hill slopes using
GraphPad Prism.
SARS-CoV-2 production
Batches of the BetaCoV/England/02/2020 (Public Health England) strain of the SARS-CoV-2
virus were produced as in our accompanying manuscripts using VERO E6 cells. A 6-well
plate plaque assay was then used to determine plaque forming units (PFU) per ml.
Viral infectivity assay
Viral infectivity assays were performed as in our accompanying manuscripts. Briefly, 96-well
imaging plates (Greiner 655090) were seeded with VERO E6 cells and cultured overnight.
The next day, the media was replaced with fresh growth media, followed by addition of drug
compounds. Finally, the cells were infected by SARS-CoV2 with a final MOI of 0.5 PFU/cell.
22 h post infection, cells were fixed, permeabilised, and stained for SARS-CoV2 N protein
using Alexa488-labelled-CR3009 antibody and cellular DNA using DRAQ7 (ABCAM).
Imaging was carried out using an Opera Phenix (Perkin Elmer) and fluorescent areas and
intensity calculated using the Phenix-associated software Harmony (Perkin Elmer).
Alexa488/N intensities were normalised to DRAQ7/DNA, and to vehicle only samples.
Data Availability Statement
All data associated with this paper will be deposited in FigShare (https://figshare.com/).

Author Contributions
Berta Canal: Conceptualisation, Methodology, Validation, Formal analysis, Investigation,
Resources, Writing ‚Äì Original Draft, Writing ‚Äì Review and Editing, Visualisation. Allison W.
McClure: Conceptualisation, Methodology, Validation, Formal analysis, Investigation,
Resources, Writing ‚Äì Original Draft, Writing ‚Äì Review and Editing, Visualisation. Joseph F.
Curran: Conceptualisation, Methodology, Validation, Formal analysis, Investigation,
Resources, Writing ‚Äì Original Draft, Writing ‚Äì Review and Editing, Visualisation. Mary Wu:
Methodology, Investigation, Resources. Rachel Ulferts: Methodology, Investigation. Florian
Weissmann: Resources. Jingkun Zeng: Resources, Software. Agustina P. Bertolin:
Resources. Jennifer C. Milligan: Investigation, Software. Souradeep Basu: Investigation.
Lucy S. Drury: Investigation. Tom Deegan: Resources. Ryo Fujisawa: Resources. Emma
L. Roberts: Resources. Clovis Basier: Resources. Karim Labib: Supervision. Rupert
Beale: Supervision. Michael Howell: Supervision. John F.X Diffley: Conceptualisation,

17

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Methodology, Writing ‚Äì Review and Editing, Supervision, Project administration, Funding
acquisition.

Acknowledgements
We thank the Crick high-throughput screen (HTS) science technology platform (STP) for
providing the chemical library and for help with screen design and analysis and are grateful
to MRC Reagents and Services (https://mrcppureagents.dundee.ac.uk/) for providing
DU70487 DNA construct for nsp14. We thank the Fermentation unit of the Crick Structural
biology STP for large scale protein expression. We thank David McClure for help with screen
analysis. We thank Anne Early for ordering supplies and hit compounds. We thank Chris
Smith for help with initial screen design and concepts. This work was supported by the
Francis Crick Institute, which receives its core funding from Cancer Research UK
(FC001066), the UK Medical Research Council (FC001066), and the Wellcome Trust
(FC001066). This work was also funded by a Wellcome Trust Senior Investigator Award
(106252/Z/14/Z) to J.F.X.D. BC and FW have received funding from the European Union's
Horizon 2020 research and innovation programme under the Marie Sk≈Çodowska-Curie grant
agreement Nos 895786 and 844211. JZ has received funding from a Ph.D. fellowship
awarded by Boehringer Ingelheim Fonds.

18

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.

The species Severe acute respiratory syndrome-related coronavirus: classifying
2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020. 5(4): p. 536-544.
Zhou, P., et al., A pneumonia outbreak associated with a new coronavirus of
probable bat origin. Nature, 2020. 579(7798): p. 270-273.
Xiong, T.Y., et al., Coronaviruses and the cardiovascular system: acute and longterm implications. Eur Heart J, 2020. 41(19): p. 1798-1800.
Zhao, Y.M., et al., Follow-up study of the pulmonary function and related
physiological characteristics of COVID-19 survivors three months after recovery.
EClinicalMedicine, 2020. 25: p. 100463.
Huerga Encabo, H., et al., Human Erythroid Progenitors Are Directly Infected by
SARS-CoV-2: Implications for Emerging Erythropoiesis in Severe COVID-19
Patients. Stem Cell Reports, 2021. 16(3): p. 428-436.
Hu, B., et al., Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews
Microbiology, 2021. 19(3): p. 141-154.
Totura, A.L. and S. Bavari, Broad-spectrum coronavirus antiviral drug discovery.
Expert Opin Drug Discov, 2019. 14(4): p. 397-412.
Medline, A., et al., Evaluating the impact of stay-at-home orders on the time to reach
the peak burden of Covid-19 cases and deaths: does timing matter? BMC Public
Health, 2020. 20(1): p. 1750.
Cui, J., F. Li, and Z.-L. Shi, Origin and evolution of pathogenic coronaviruses. Nature
Reviews Microbiology, 2019. 17(3): p. 181-192.
Peiris, J.S., et al., Coronavirus as a possible cause of severe acute respiratory
syndrome. Lancet, 2003. 361(9366): p. 1319-25.
Zaki, A.M., et al., Isolation of a novel coronavirus from a man with pneumonia in
Saudi Arabia. N Engl J Med, 2012. 367(19): p. 1814-20.
Agostini, M.L., et al., Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734)
Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio,
2018. 9(2).
Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently emerged
novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020. 30(3): p. 269-271.
Yin, W., et al., Structural basis for inhibition of the RNA-dependent RNA polymerase
from SARS-CoV-2 by remdesivir. Science, 2020. 368(6498): p. 1499-1504.
Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J
Med, 2020. 383(19): p. 1813-1826.
Pan, H., et al., Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity
Trial Results. N Engl J Med, 2020.
V'Kovski, P., et al., Coronavirus biology and replication: implications for SARS-CoV2. Nat Rev Microbiol, 2020: p. 1-16.
Finkel, Y., et al., The coding capacity of SARS-CoV-2. Nature, 2021. 589(7840): p.
125-130.
Sevajol, M., et al., Insights into RNA synthesis, capping, and proofreading
mechanisms of SARS-coronavirus. Virus Res, 2014. 194: p. 90-9.
Minskaia, E., et al., Discovery of an RNA virus 3'->5' exoribonuclease that is critically
involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A, 2006. 103(13): p.
5108-13.
Chen, Y., et al., Functional screen reveals SARS coronavirus nonstructural protein
nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A, 2009. 106(9):
p. 3484-9.
Bouvet, M., et al., In vitro reconstitution of SARS-coronavirus mRNA cap methylation.
PLoS Pathog, 2010. 6(4): p. e1000863.
Ma, Y., et al., Structural basis and functional analysis of the SARS coronavirus
nsp14-nsp10 complex. Proc Natl Acad Sci U S A, 2015. 112(30): p. 9436-41.

19

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.

Moser, M.J., et al., The proofreading domain of Escherichia coli DNA polymerase I
and other DNA and/or RNA exonuclease domains. Nucleic Acids Res, 1997. 25(24):
p. 5110-8.
Zuo, Y. and M.P. Deutscher, Exoribonuclease superfamilies: structural analysis and
phylogenetic distribution. Nucleic Acids Res, 2001. 29(5): p. 1017-26.
Bouvet, M., et al., RNA 3'-end mismatch excision by the severe acute respiratory
syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex.
Proc Natl Acad Sci U S A, 2012. 109(24): p. 9372-7.
Gorbalenya, A.E., et al., Nidovirales: evolving the largest RNA virus genome. Virus
Res, 2006. 117(1): p. 17-37.
Eckerle, L.D., et al., High fidelity of murine hepatitis virus replication is decreased in
nsp14 exoribonuclease mutants. J Virol, 2007. 81(22): p. 12135-44.
Smith, E.C., et al., Coronaviruses lacking exoribonuclease activity are susceptible to
lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS
Pathog, 2013. 9(8): p. e1003565.
Graepel, K.W., et al., Proofreading-Deficient Coronaviruses Adapt for Increased
Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating
Mutations. mBio, 2017. 8(6).
Ogando, N.S., et al., The Curious Case of the Nidovirus Exoribonuclease: Its Role in
RNA Synthesis and Replication Fidelity. Front Microbiol, 2019. 10: p. 1813.
Smith, E.C., et al., Mutations in coronavirus nonstructural protein 10 decrease virus
replication fidelity. J Virol, 2015. 89(12): p. 6418-26.
Eckerle, L.D., et al., Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus
Replication Is Revealed by Complete Genome Sequencing. PLOS Pathogens, 2010.
6(5): p. e1000896.
Subissi, L., et al., One severe acute respiratory syndrome coronavirus protein
complex integrates processive RNA polymerase and exonuclease activities. Proc
Natl Acad Sci U S A, 2014. 111(37): p. E3900-9.
Yan, L., et al., Cryo-EM Structure of an Extended SARS-CoV-2 Replication and
Transcription Complex Reveals an Intermediate State in Cap Synthesis. Cell, 2021.
184(1): p. 184-193.e10.
Ogando, N.S., et al., The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical
for Replication of MERS-CoV and SARS-CoV-2. J Virol, 2020. 94(23).
Becares, M., et al., Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in
Modulation of the Innate Immune Response. J Virol, 2016. 90(11): p. 5399-5414.
Case, J.B., et al., Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required
for Resistance to Innate Immunity. Journal of Virology, 2018. 92(1): p. e01531-17.
Gribble, J., et al., The coronavirus proofreading exoribonuclease mediates extensive
viral recombination. PLoS Pathog, 2021. 17(1): p. e1009226.
Ashburn, T.T. and K.B. Thor, Drug repositioning: identifying and developing new
uses for existing drugs. Nature Reviews Drug Discovery, 2004. 3(8): p. 673-683.
Guy, R.K., et al., Rapid repurposing of drugs for COVID-19. Science, 2020.
368(6493): p. 829-830.
Irwin, J.J., et al., An Aggregation Advisor for Ligand Discovery. J Med Chem, 2015.
58(17): p. 7076-87.
Richard B. Hallick, B.K.C., Patrick W. Gray and Emil M. Orozco, Jr, Use of
aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid isolation. 1977.
Zheng, W., W. Sun, and A. Simeonov, Drug repurposing screens and synergistic
drug-combinations for infectious diseases. British Journal of Pharmacology, 2018.
175(2): p. 181-191.
Bouvet, M., et al., Coronavirus Nsp10, a critical co-factor for activation of multiple
replicative enzymes. J Biol Chem, 2014. 289(37): p. 25783-96.
Saramago, M., et al., New targets for drug design: Importance of nsp14/nsp10
complex formation for the 3‚Äô-5‚Äô exoribonucleolytic activity on SARS-CoV-2. bioRxiv,
2021: p. 2021.01.07.425745.
20

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.

Totura, A.L. and R.S. Baric, SARS coronavirus pathogenesis: host innate immune
responses and viral antagonism of interferon. Current Opinion in Virology, 2012. 2(3):
p. 264-275.
Zhang, Q., K. Shi, and D. Yoo, Suppression of type I interferon production by porcine
epidemic diarrhea virus and degradation of CREB-binding protein by nsp1. Virology,
2016. 489: p. 252-68.
Robson, F., et al., Coronavirus RNA Proofreading: Molecular Basis and Therapeutic
Targeting. Mol Cell, 2020. 79(5): p. 710-727.
Gonzalez, R.G., R.S. Haxo, and T. Schleich, Mechanism of action of polymeric
aurintricarboxylic acid, a potent inhibitor of protein-nucleic acid interactions.
Biochemistry, 1980. 19(18): p. 4299-4303.
Baddock, H.T., et al., Characterisation of the SARS-CoV-2 ExoN (nsp14-ExoNnsp10) complex: implications for its role in viral genome stability and inhibitor
identification. bioRxiv, 2020: p. 2020.08.13.248211.
He, R., et al., Potent and selective inhibition of SARS coronavirus replication by
aurintricarboxylic acid. Biochem Biophys Res Commun, 2004. 320(4): p. 1199-203.
Park, J.G., et al., Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid.
Front Microbiol, 2019. 10: p. 718.
Lee, M., et al., Selective inhibition of the membrane attack complex of complement
by low molecular weight components of the aurin tricarboxylic acid synthetic
complex. Neurobiol Aging, 2012. 33(10): p. 2237-46.
Klein, P., et al., In vitro and in vivo activity of aurintricarboxylic acid preparations
against Cryptosporidium parvum. Journal of Antimicrobial Chemotherapy, 2008.
62(5): p. 1101-1104.
Puel, O., P. Galtier, and I.P. Oswald, Biosynthesis and toxicological effects of patulin.
Toxins (Basel), 2010. 2(4): p. 613-31.
Arzu Kockaya, E., et al., Evaluation of patulin toxicity in the thymus of growing male
rats. Arh Hig Rada Toksikol, 2009. 60(4): p. 411-8.
Saxena, N., et al., Role of mitogen activated protein kinases in skin tumorigenicity of
patulin. Toxicol Appl Pharmacol, 2011. 257(2): p. 264-71.
Saxena, N., et al., Patulin causes DNA damage leading to cell cycle arrest and
apoptosis through modulation of Bax, p(53) and p(21/WAF1) proteins in skin of mice.
Toxicol Appl Pharmacol, 2009. 234(2): p. 192-201.
Seigle-Murandi, F., et al., Antitumor activity of patulin and structural analogs.
Pharmazie, 1992. 47(4): p. 288-91.
Clarke, M., The 1944 patulin trial of the British Medical Research Council. J R Soc
Med, 2006. 99(9): p. 478-80.
Stein, A., et al., Key steps in ERAD of luminal ER proteins reconstituted with purified
components. Cell, 2014. 158(6): p. 1375-1388.
Weissmann, F., et al., biGBac enables rapid gene assembly for the expression of
large multisubunit protein complexes. Proc Natl Acad Sci U S A, 2016. 113(19): p.
E2564-9.
Trowitzsch, S., et al., New baculovirus expression tools for recombinant protein
complex production. J Struct Biol, 2010. 172(1): p. 45-54.

21

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure Legends
Figure 1. Purified nsp14/10 exoribonuclease assay.
A. Coomassie-stained SDS-PAGEs of purified nsp14 (60 kDa) and nsp10 (15 kDa) proteins.
B. Reaction scheme for gel-based exonuclease assay performed with the Cy5-substrate.
Cleavage of the dsRNA substrate can be detected in TBE-urea polyacrylamide gels with the
Cy5-substrate migrating faster as it is cleaved in the 3‚Äô to 5‚Äô direction. C. Nuclease reactions
containing 75 nM or 200 nM nsp14 or Flag-His-nsp14 and 50 nM Cy5-substrate. Reactions
performed at RT for 30 min visualised by TBE-urea polyacrylamide gels. D. As in C, first
lane shows 400 nM Flag-nsp10 and remaining lanes show titration of nsp10-His-Flag over
50 nM nsp14. E. Purified co-expressed nsp14 and nsp10 complexes. F. As in C, titration of
the co-expressed nsp14/10 complex and comparison to 50 nM nsp14 + 400 nM nsp10. G.
As in C, reactions containing 75 nM or 200 nM of the co-expressed complexes nsp14/nsp10His-Flag and Flag-nsp14/nsp10.
Figure 2. RiboGreen assay for nsp14/10 exoribonuclease activity
A. Reaction scheme for exonuclease activity detected by RiboGreen fluorescence. B.
Titration of the Cy5-dsRNA substrate incubated with RiboGreen and detected by microplate
reader. C. Cy5-dsRNA substrate was incubated with RiboGreen for 3 min or 60 min prior to
fluorescence detection. Error bars represent standard deviation from the mean. D.
Exonuclease reactions from Figure 1F. 30 min reactions with titration of the co-expressed
nsp14/10 complex and 50 nM of Cy5-substrate and comparison to 50 nM nsp14 + 400 nM
nsp10, followed by RiboGreen incubation.
Figure 3. The nsp14-10 fusion protein is an efficient exonuclease
A. Schematic of nsp14-10 and nsp10-14 fusion proteins. B. Coomassie-stained SDSPAGEs of purified nsp14-10 and nsp10-14 fusion proteins (75 kDa). Connecting linker is
GGSGGS. C. Time course of exonuclease reaction containing 5 nM nsp10-14 fusion and 50
nM Cy5-substrate. Reactions were split in half and separated on TBE-urea polyacrylamide
gels or incubated with RiboGreen. D. Exonuclease reactions containing a titration of nsp1014 and nsp14-10 fusion proteins and 50 nM Cy5-substrate performed for 30 minutes. E.
Titration of nsp10-14 fusion in exonuclease assay with 50 nM unlabelled dsRNA substrate
after 30 min detected by RiboGreen. Error bars represent standard deviation from the mean.
Figure 4. High-throughput screen to identify SARS-CoV-2 nsp14/10 exoribonuclease
inhibitors.
A. Reaction scheme for the kinetic nuclease assay performed with the Cy3-dsRNA
substrate. Cleavage of the dsRNA substrate by nsp14/nsp10 nuclease can be detected by
the appearance of Cy3 fluorescence. B. Exonuclease reactions containing 5 nM nsp10-14

22

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

fusion protein and 180 nM Cy3-dsRNA substrate or 180 nM Cy3-dsDNA substrate and
detected after 1 h. C. Cy3-dsRNA substrate titration (15 - 500 nM) performed in the
presence of 0.5 nM nsp10-14 with fluorescence monitored over time. D. Non-linear fit to
Michaelis-Menten equation of slopes from C. E. Titration of nsp10-14 with 50 nM Cy3dsRNA substrate. F. Normalised residual activity of screen sample wells in low and high
concentrations. G. Z-scores of samples plotted as low versus high concentration. In all
panels, error bars represent standard deviation from the mean.
Figure 5. Patulin and aurintricarboxylic acid (ATA) inhibit nsp14/10 nuclease in vitro.
A. Nuclease reactions containing 1 nM nsp10-14 fusion protein and 50 nM of Cy5-dsRNA
substrate alone or in the presence of 5 ¬µM or 25 ¬µM of each of the 12 top hits (in blue)
selected from both HTS screens. Reactions were performed for 5 minutes at RT and
visualised by TBE-urea polyacrylamide gels. B. 200 nM co-expressed nsp14/10 complex
was pre-incubated with the specified concentration of patulin, and nuclease reactions were
performed in the presence of 50 nM Cy5-dsRNA substrate for 5 min and visualised by TBEurea polyacrylamide gels. C, D. Nuclease reactions containing 1 nM nsp10-14 fusion
protein, 0.06 ng/ul RNase A (Qiagen) and 0.5 mU/ul benzonase (Sigma) nucleases and 50
nM Cy5-dsRNA substrate in the presence of 0, 5, 25 or 50 ¬µM patulin (C) or ATA (D). High
and low image saturations are shown. E, F. Dose-response curves and IC50 values of patulin
(E) and ATA (F). IC50 values were calculated as described in Experimental Procedures.
Nuclease activities (slope) for each patulin and ATA concentration were obtained from
triplicate kinetic reactions (20 min) in the presence of 0.5 nM nsp10-14 fusion and 50 nM
Cy3-substrate (Supplementary Figure S4E, S5F). Patulin and ATA were pre-incubated with
nsp10-14 for 10 minutes prior to the addition of the substrate. Graphs represent % of control
activity (slope) vs. the log10 of the concentration of patulin or ATA. In E and F, error bars
represent standard deviation from the mean.
Figure 6. Patulin and aurintricarboxylic acid (ATA) inhibit SARS-CoV-2 viral growth in
VERO E6 cells.
A. After VERO E6 cell seeding, media was replaced with fresh media containing indicated
concentrations of patulin followed by infection with SARS-CoV-2. 22 h post-infection, wells
were stained with DRAQ7 (cells) and AlexaFluor-conjugated antibodies against the SARSCoV-2 N protein (virus). Quantification is shown at right (mean +/- SD). Quantification of viral
area is normalised to cell area. B. Experiment performed as in A with lower dose titration of
patulin. C. Experiment as in A, with titration of aurintricarboxylic acid (ATA). D. Experiment
as in A, with combined treatment of 0.5 ¬µM remdesivir. Note the black line indicating patulin
only treatment is the same as in A. E. Experiment as in C, with combined treatment of 0.5
¬µM remdesivir. Note the black line indicating ATA only treatment is the same as in C.

23

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Material
Supplementary Figure S1. Titration of RiboGreen
RiboGreen was diluted as indicated and then incubated with 4 to 64 nM unlabelled dsRNA
substrate prior to fluorescence detection.
Supplementary Figure S2. The nsp10-14 fusion functions as a methyltransferase
The nsp10-14 fusion protein was assayed for methyltransferase activity by the detection of
formed SAH following methyltransferase assay (see Experimental Procedures). The
methyltransferase reaction was run in either the absence of 10 nM nsp10-14, 1 ŒºM SAM
methyl donor, 0.11 mM GpppA cap analogue, or in the presence of all three components. In
addition, the methyltransferase reaction was conducted in the presence of 2.5 ŒºM and 25
ŒºM of the pan-methyltransferase inhibitor Sinefungin, which acts as a competitive inhibitor
(with respect to SAM) towards SAM-dependent methyltransferases. Error bars represent
standard deviation from the mean.
Supplementary Figure S3. Ribogreen-based screen to identify SARS-CoV-2 nsp14/10
exoribonuclease inhibitors.
A. Determination of initial rate of reaction when varying unlabelled dsRNA substrate
concentration (15 ‚Äì 250 nM). Reactions were carried out using 5 nM nsp10-14 fusion
enzyme and stopped after 0, 3 and 6 minutes before dsRNA detection with RiboGreen. B.
Non-linear Michaelis-Menten fit for enzyme kinetics data generated by substrate titration
from A. C. Normalised residual activity for screen samples at low and high concentrations.
D. Selected compounds were assayed for autofluorescence at 525 nm (RiboGreen
wavelength). Error bars represent standard deviation from the mean.
Supplementary Figure S4. Patulin and aurintricarboxylic acid inhibit nsp14/10
nuclease in vitro.
A. 30 nM of co-expressed nsp14/10 complex was pre-incubated with 3 - 200 ¬µM of patulin,
and nuclease reactions were performed in the presence of 50 nM Cy5-dsRNA substrate at
RT for 5 min and visualised in TBE-urea polyacrylamide gels. B. Nuclease reactions
containing titration of RNase A or benzonase and 50 nM Cy5-dsRNA substrate were
performed at RT for 5 minutes and visualised by TBE-urea polyacrylamide gels. C, D.
Representation of the chemical structures of patulin (C) and ATA (D). E, F. Kinetic nuclease
reactions (20 min) were performed in triplicates in the presence of 0.5 nM nsp10-14 fusion,
50 nM Cy3-dsRNA substrate and 0 to 160 ¬µM patulin (C) or ATA (D). Patulin and ATA were
pre-incubated with nsp10-14 for 10 minutes prior to the addition of the substrate. These
reactions were used to calculate the IC50 of the inhibitors (see Experimental Procedures).
Error bars represent standard deviation from the mean. G, H. Drug quenching test

24

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

performed by assessing fluorescence of a Cy3-labelled oligonucleotide (50 nM) preincubated 10 minutes in the presence of a titration (0 ‚Äì 160 ¬µM) of patulin and ATA
respectively.
Supplementary Figure S5. Patulin and remdesivir are not synergistic to inhibit SARSCoV-2 viral growth in VERO cells.
SARS-CoV-2 infectivity assays in VERO E6 assay performed as in Figure 5A with the
indicated concentrations of patulin and remdesivir. For each condition, quantifications
represent viral area normalised to the no drug well. Error bars represent standard deviation
from the mean.

25

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 1

B

kDa

ns
p1
4
3x
Fla
gn
3x
Fla sp10
g
ns -6H
p1
i
0- s-ns
6H
p
is- 14
3x
Fla
g

A

Cy5-dsRNA substrate

5‚Äô Cy5

200
100
70

3‚Äô

3‚Äô

+nsp14/10

FH-nsp14
nsp14

50
25

5‚Äô

F-nsp10,
nsp10-HF

15
Insect
cells

E. coli

D
+F-nsp10

50
100
200
400
50
100
200
400

75 ns
p1
200
4
75 F
Hns
200
p1

+nsp10-HF

(nM)

FH-nsp14

Uncleaved

nsp14

400

4

C

nsp14 (50 nM)

Cleaved

E

F
0
3
6
12
25
50
100
200
50
+4 nM
00 ns
nM p14
ns
p1
0

Fla
ns g-ns
p1
p
4/n 14/
sp nsp
10
10
-6
Hi
s-3
xF
F-nsp14
nsp14

nsp10-HF
nsp10

15

t
li
co nsec
I ells
c

F-

25

75
200
75
200

ns

p1

50

ns
ns p1
p1 0 4/ HF
ns
p1
0

100
70

4/

G

200

E.

F-nsp14/nsp10 (nM)

3x

kDa

-H

lag

F

(nM)

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 2

B

R2 = 0.9998

2048
1024
512
256
128
64
2

8 16 32 64 128 256 512
[dsRNA] (nM)

0
3

60

(min)

Incubation time with RiboGreen

No substrate

2
0
6

2

4

3

4

6

0

6

dsRNA
RiboGreen Fluorescence (x104 a.u.)

dsRNA
RiboGreen Fluorescence (x104 a.u.)

D

F-nsp14/nsp10 (nM)

200

C

4

50

-

4096

100

3‚Äô

8192

25

+RiboGreen
readout
5‚Äô
+
+nsp14/10
3‚Äô

1/400 dilution RiboGreen
No RiboGreen

16384

12

unlabelled dsRNA substrate
5‚Äô

32768
RiboGreen Fluorescence (a.u.)

A

50
m
+4 Mn
s
0
ns 0 m p14
p1 M
0-H
F

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 3

C

25
14His-SUMO nsp10 -GGSGGS-

nsp14

15
E. coli

0
0.75
1.5
2
3
4
5
10
30
3
2
1
0

Time (min)

fusion protein (nM)

nsp10-14 fusion (nM)

40

20

10

5

2.5

0

1.25

2

0.6

200

100

50

25

12

6

3

1.5

0

0

2

4

0.3

4

6

0

nsp10-14 fusion
nsp14-10 fusion

6

dsRNA
Ribogren Fluorescence (x104 a.u.)

E
dsRNA
Ribogren Fluorescence (x104 a.u.)

D

4

30

50

nsp10-14 fusion:

5

25

nsp14
+
nsp10

20

100
70

(min)
Uncleaved
Cleaved

15

kDa
200

5

-GGSGGS- nsp10

0

nsp14

14His-SUMO

dsRNA
Ribogren Fluorescence (x104 a.u.)

nsp14-10 fusion:

nsp10-14 fusion

10

B
ns
p1
4
ns -10
fus
p1
014 ion
fus
ion

A

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 4

Cy3-dsRNA substrate
Cy3
5‚Äô
Quencher

3‚Äô
dU
+nsp14/10

C

6
4
2
0

-

+

-

+ nsp10-14

RNA cleavage
Cy3 Fluorescence (x104 a.u.)

B
RNA cleavage
Cy3 Fluorescence (x104 a.u.)

A

25
20

500
250
125
62.5
31.25
15.625

15
10

RNA
DNA
Cy3-substrate

D

[substrate]
(nM)

5

0

10

20 30
Time (min)

40

E
VMAX = 510 nM/min

400
300
200

KM = 40 nM

100
0

0

100

200

30

RNA cleavage
Cy3 Fluorescence (x103 a.u.)

Velocity (nM/min)

500

300

400

25

1
0.75
0.5
0.25
0.125
0.0625
0.03125
No Enzyme

20
15
10
5
0

500

[nsp10-14] (nM)

0

5

10

15

20

Time (min)

[Cy3 substrate] (nM)

G
1.50

Low concentration (1.25 ¬µM)

1.25
Z-score
Low concentration

1.00
0.75

-20

0.50

-10

0.25
0

-10

1.50

High concentration (3.75 ¬µM)

1.25
1.00
-20

0.75
0.50
0.25
0
0

1000 2000 3000 4000 5000 6000
Sample well number

Z-score
High concentration

Normalised residual activity

Normalised residual activity

F

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 5

A

B

25 ¬µM

200 nM F-nsp14/10
0
4
8
16
31
62
125
250
500
1000
2000

+ nsp10-14
- Enzyme
Patulin
Mercaptopurine
ATA
PBIT
Coptisine
Betaxolol
Curcumin III
Dem.-curcumin
JNJ-1661010
Phenazin
Betahistine
Valinomycin

nsp10-14

Patulin (¬µM)

Uncleaved
Cleaved

5 ¬µM

- Enzyme
0
5
25
50
0
5
25
50
0
5
25
50

D
- Enzyme
0
5
25
50
0
5
25
50
0
5
25
50

C
nsp10-14 RNase A benzonase

nsp10-14 RNase A benzonase

high
saturation
1 2 3 4 5 6 7 8 9 10 111213 (lanes)

F

100

IC50 = 1.8 ¬µM
Hill slope = -1.3
R2 = 0.99

% Control Activity

75
50
25
0
-25

1 2 3 4 5 6 7 8 9 10 111213 (lanes)

10-2

10-1

100

101

[Patulin] (¬µM)

102

103

100

% Control Activity

E

ATA (¬µM)

low
saturation

low
saturation

high
saturation

Patulin (¬µM)

IC50 = 10.3 ¬µM
Hill slope = -1.9
R2 = 0.99

75
50
25
0
-25

10-2

10-1

100

101

[ATA] (¬µM)

102

103

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 6

hi
cle
ve

un

in
fe
c

te
d

[Patulin] (¬µM)
0.1

0.3

1

3

10

30
cells
virus

% Vehicle Control

A
150
125
100
75
50
25
0

viral area
cell area

0.1

1
10
[Patulin] (¬µM)

B
1

2.5

5

7.5

10

20
cells
virus

C

3

10

30

100

% Vehicle Control

1

300

ve

hi

cle

[Aurintricarboxylic acid] (¬µM)

cells
virus

D

% Vehicle Control

hi
cle
ve

un

in
fe
c

te
d

[Patulin] (¬µM)

viral area
cell area

150
100
50
0

1

10
[Patulin] (¬µM)

100
75
50

viral area
cell area

25
0

1
10
100
[Aurintricarboxylic acid] (¬µM)

E
150
125
100
75
50
25
0

viral area (ATA)
viral area (ATA + 0.5 ¬µM remdesivir)
% Vehicle Control

% Vehicle Control

viral area (Patulin)
viral area (Patulin + 0.5 ¬µM remdesivir)

0.1

1
10
[Patulin] (¬µM)

100
75
50
25
0

1
10
100
[Aurintricarboxylic acid] (¬µM)

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

RiboGreen Fluorescence (a.u.)

Supplementary Figure S1

4096
2048

Dilution of RiboGreen
1/200
1/400
1/800
1/1600
1/3200
1/6400
No RiboGreen

1024
512
256
128
64
2

4

8

16

32

[dsRNA] nM

64

128

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Normalised HTRF Signal

Supplementary Figure S2

1.5
1
0.5

0
fusion nsp10-14
SAM
GpppA
Sinefungin

+

+

--

+

+

+

+
--

-

+

+

+

+

+

+

+

+

+

--

--

-

-

2.5¬µM 25¬µM

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Figure S3

B

25
20

250
125

15

62.5
31.25

10

15.625

5
0
0

800
600

R2 = 0.95

400

KM = 66 nM

200
0

3

VMAX = 1089

1000

[Substrate] (nM)

Initial Velocity (a.u./min)

dsRNA
RiboGren Fluorescence (x103 a.u.)

A

6

0

50

100

150

200

250

[dsRNA substrate] (nM)

Time (min)

C

D
Low concentration (1.25 ¬µM)

60000

1.25

Fluorescence at 525 nm

Normalised Residual Activity

1.5

1.0
0.75
0.5
0.25

40000

20000

0.0

0
de
m
Bi
et
sho
de
xy
D
m
M
et cur
S
cu O
ho
m
xy
in
cu
(1
rc
um )
in
(2
)
Su
r
am
C
D
em AR
in
M
et
1ho
IN
xy
cu -1
rc
um
in

High concentration (3.75 ¬µM)

1.25
1.0

s-

0.75

Bi

Normalised Residual Activity

1.5

0.5
0.25
0.0
2000
4000
sample well number

6000

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Figure S4

B
+ F-nsp14/10
- Enzyme
3.125
6.25
12.5
25
50
100
200

A

RNase A
(ng/¬µl)

benzonase
(mU/¬µl)

- Enzyme
0.06
0.13
0.25
0.5
1
2
0.02
0.03
0.06
0.13
0.25
0.5

30 nM F-nsp14/10

Patulin (¬µM)
Uncleaved

Cleaved?

Cleaved

Cleaved

C

D

O

O

OH

O

OH

O

OH

O
O

OH

HO
O

F
[Patulin] (¬µM)
0
0.3125
0.625
1.25
2.5
5
10
20
40
80
160

nsp10-14 activity
Cy3 Fluorescence (x103 a.u.)

8
6
4
2
0

0

5

10

15

[ATA] (¬µM)

8
nsp10-14 activity
Cy3 Fluorescence (x103 a.u.)

E

Aurintricarboxylic acid (ATA)

6
4
2
0

20

0
0.3125
0.625
1.25
5
10
20
40
80
160

0

Time (min)

Quenching control
Cy3 Fluorescence (x103 a.u.)

20
15
10
5
0

[Patulin] (¬µM)

10

15

20

Time (min)

H

25

0
0.3125
0.625
1.25
2.5
5
10
20
40
80
160

Quenching control
Cy3 Fluorescence (x103 a.u.)

G

5

25
20
15
10
5
0

0
0.3125
0.625
1.25
2.5
5
10
20
40
80
160

Patulin

OH

[ATA] (¬µM)

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Figure S5

ve

hi
cle

[Remdesivir] (¬µM)
0.5

1

5

10

50

100
cells

+ 5 ¬µM patulin

cells
virus

virus

+ 3 ¬µM patulin

75

+ 5 ¬µM patulin

50
25
0
0.1

cells

No patulin

100
% Vehicle Control

+ 3 ¬µM patulin

virus

1

10

[Remdesivir] (¬µM)

100

Supplementary Table S1. Cloning strategies
Construct name

Construct
number

Construct features (vector_insert)

Insert origin

Oligos/sites
Vector

Antibiotic
resistance

codon optimised
nsp10 (Genewiz)

NdeI, BamHI

Amp

non-optimised nsp14
(MRC)

1, 2

Kan

Constructs for expression in E. coli
SARS-CoV-2 3xFlag-nsp5CS-nsp10
SARS-CoV-2 His-SUMO-nsp14

169157
(Addgene ID)
DU70487
(MRC PPU)

pET11a_3xFlag-nsp5CS(VRLQ)-nsp10
pK27SUMO_14His-K27SUMO-nsp14

SARS-CoV-2 nsp10

169158
(Addgene ID)

pCOLADuet-1_methionine-nsp10

codon optimised
nsp10 (Genewiz)

NcoI, BamHI

Kan

SARS-CoV-2 3xFlag-nsp5CS-nsp14

169159
(Addgene ID)

pET11a_3xFlag-nsp5CS(VATLQ)-nsp14

codon optimised
nsp14 (Genewiz)

NdeI, BamHI

Amp

SARS-CoV-2 His-SUMO-nsp14-nsp10 fusion

169160
(Addgene ID)

pK27SUMO_14His-K27SUMO-nsp14(GGS)2-nsp10

codon optimised
nsp10 and 14

1, 2

Kan

169161
(Addgene ID)
Constructs for expression in baculovirus-infected insect cells

pK27SUMO_14His-K27SUMO-nsp10(GGS)2-nsp14

codon optimised
nsp10 and 14

1, 2

Kan

SARS-CoV-2 His-SUMO-nsp10-nsp14 fusion

SARS-CoV-2 nsp10-His-3xFlag

169162
(Addgene ID)

pBIG1b_methionine-nsp10-6His-3xFlag

codon optimised
nsp10 (GeneArt)

BamHI,
HindIII

Amp +
Spectin.

SARS-CoV-2 3xFlag-His-nsp5CS-nsp14

169163
(Addgene ID)

pBIG1a_3xFlag-6His-nsp5CS(SAVLQ)nsp14

codon optimised
nsp14 (GeneArt)

BamHI,
HindIII

Amp +
Spectin.

SARS-CoV-2 nsp14/nsp10-His-3xFlag

169164
(Addgene ID)

pBIG2ab_methionine-nsp14/methioninensp10-6His-3xFlag

codon optimised
nsp14 and 10

PmeI

Amp. +
Chlor.

*CS = cleavage site

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Table S2. Cloning oligos
Oligo Oligo sequence
1

GCCACCAATCTGTTCTCTGTG

2

TAATAAgcggccgcacatcac

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Table S3. Purification strategies
Used to express

Codon
optimisation

SARS-CoV-2 3xFlag-nsp5CSnsp10

Individual nsp10

E. coli

SARS-CoV-2 His-SUMO-nsp14

Individual nsp14

Plasmid name

SARS-CoV-2 nsp10

Complex
nsp14/10

Purification steps
PD Œ±-Flag > MonoQ > Dialysis

Non-optimised PD NiNTA > Ulp1 > Superdex200
E. coli
PD Œ±-Flag > MonoQ > Superdex200

SARS-CoV-2 3xFlag-nsp5CSnsp14
SARS-CoV-2 His-SUMO-nsp14nsp10 fusion
SARS-CoV-2 His-SUMO-nsp10nsp14 fusion

nsp14-10 fusion

E. coli

PD NiNTA > Ulp1 > MonoQ > Superdex200

nsp10-14 fusion

E. coli

PD NiNTA > Ulp1 > MonoQ > Superdex200

SARS-CoV-2 nsp10-His-3xFlag

Individual nsp10

Insect cells

PD Œ±-Flag > MonoQ > Dialysis

Individual nsp14

Insect cells

PD Œ±-Flag > Superdex200

Complex
nsp14/10

Insect cells

PD Œ±-Flag > MonoQ > Superdex200

SARS-CoV-2 3xFlag-His-nsp5CSnsp14
SARS-CoV-2 nsp14/nsp10-His3xFlag

E. coli

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Table S4. Substrate oligos
Oligo

Substrate

Oligo sequence (5' ‚Üí 3')

i

Top unlabelled RNA

AAUAGCUUCUUAGGAGAAUGAC

ii

Top Cy5 RNA

Cy5-AAUAGCUUCUUAGGAGAAUGAC

iii

Bottom unlabelled RNA

CCCUAUCGUCAUUCUCCUAAGA

iv

Top Cy3 RNA

Cy3-GGUAGUAAUCCGCUC

v

Bottom quencher RNA

UUUUUUUUUUUUUUUUUUUUGAGCGGAUUACUACC-Iowa
Black RQ

vi

Top Cy3 DNA

Cy3-GGTAGTAATCCGCTC

vii

Bottom quencher DNA

TTTTTTTTTTTTTTTTTTTTGAGCGGATTACTACC-Iowa
Black RQ

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438812; this version posted April 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Supplementary Table S5. Top screen hit compounds
Residual
Z score
activity (end- (end-point
point screen) screen)

Residual
Z score
activity
(kinetic
(kinetic
screen)
screen)

Chemical Name

Cat No

Aggreg.
Index
(LogP)

Patulin

NP-223

-0.4

0.89

-1.30

0.70

-4.81

Mercaptopurine

S1305

-0.4

0.96

-0.54

1.00

0.27

Aurintricarboxylic acid (ATA)

A 1895

3.8

-1.85

-31.00

0.66

-5.47

1,3-PBIT dihydrobromide
(PBIT)

P 8227

1.5

0.94

-0.77

0.82

-2.77

Coptisine chloride

HY-N0736

0.2

0.87

-1.55

0.81

-2.82

Betaxolol hydrochloride

B 5683

2.8

0.90

-1.21

0.86

-2.12

Bisdemethoxycurcumin
(Curcumin III)

2.7 (80%
HY-N0007 similarity to
aggregator)

-0.08

-11.80

0.88

-1.70

Demethyl-curcumin

2.5 (100%
MFCD034
similarity to
27310
aggregator)

0.37

-6.94

0.93

-0.84

JNJ-1661010

S2828

3.9

0.63

-4.17

0.87

-1.82

Phenazine methosulfate

MFCD000
11923

-0.4

0.83

-1.91

0.94

-0.74

Betahistine dihydrochloride

S3176

0.7

1.03

0.22

0.86

-1.97

Valinomycin

KC-140

5.1

0.98

-0.34

0.83

-2.61

